Biotech VC Forbion raises record €2.3 bn ($2.6 bn) to back 30 high-potential life-science companies
Forbion announced a record fundraising of €2.3 bn ($2.6 bn) across two new funds, bringing its assets under management to about €7.5 bn ($8.4 bn).
The capital will be allocated through the Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, aimed at supporting roughly 30 companies that the firm deems high-potential, spanning pre‑clinical to early‑stage clinical drug developers.
Forbion described its approach as therapy‑area agnostic, targeting innovative biotechs addressing unmet medical needs with novel therapeutics.
The firm also noted its participation in Gate Bioscience’s November 2025 Series B round, shortly after Gate Bioscience secured an up to $870 million deal extension with Eli Lilly.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Biotech VC Forbion raises record $2.6B to support 30 ‘high-potential’ companies”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that